VERZENIO |
ABEMACICLIB |
VERZENIOS |
LY-2835219 |
HY-16297A |
LY2835219 |
CS-1230 |
LY 2835219 |
chembl:CHEMBL3301610 |
pubchem.compound:46220502 |
chemidplus:1231929-97-7 |
drugbank:12001 |
Pharmaceutical Developer | Eli Lilly |
Source Reported Drug Name(s) | LY2835219 |
Drug Class | CDK/Rb Inhibitor |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
Drug Categories | amines |
Drug Categories | antineoplastic agents |
Drug Categories | antineoplastic and immunomodulating agents |
Drug Categories | bcrp/abcg2 inhibitors |
Drug Categories | bcrp/abcg2 substrates |
Drug Categories | cytochrome p-450 cyp1a2 inhibitors |
Drug Categories | cytochrome p-450 cyp1a2 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp2b6 inhibitors |
Drug Categories | cytochrome p-450 cyp2b6 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp2c8 inhibitors |
Drug Categories | cytochrome p-450 cyp2c8 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp2c9 inhibitors |
Drug Categories | cytochrome p-450 cyp2c9 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp2d6 inhibitors |
Drug Categories | cytochrome p-450 cyp2d6 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a inhibitors |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a4 substrates |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | heterocyclic compounds, fused-ring |
Drug Categories | kinase inhibitor |
Drug Categories | mate 1 inhibitors |
Drug Categories | mate 1 substrates |
Drug Categories | mate 1 substrates with a narrow therapeutic index |
Drug Categories | mate 2 inhibitors |
Drug Categories | mate inhibitors |
Drug Categories | mate substrates |
Drug Categories | oct2 inhibitors |
Drug Categories | p-glycoprotein inhibitors |
Drug Categories | p-glycoprotein substrates |
Drug Categories | protein kinase inhibitors |
Drug Categories | pyridines |
n/a |
n/a |
inhibitor (inhibitory) |
Details of the Assay for Interaction | CDK6/cyclin D1 complex expressed in and purified from insect cells. Assays used the methanesulfonate salt of the compound. |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
inhibitor (inhibitory) |
Details of the Assay for Interaction | CDK4/cyclin D1 complex expressed in and purified from insect cells. Assays used the methanesulfonate salt of the compound. |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
n/a |
Indication/Tumor Type | non-small cell lung carcinoma |
Response Type | sensitive |
Approval Status | Phase I |
n/a |
ABEMACICLIB | DrugBank Drug Name |
1231929-97-7 | CAS Number |
Verzenio | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
LY2835219 | Drug Trade Name |
LY2835219 | Drug Development Name |
Drug Class | CDK/Rb Inhibitor |
Source Reported Drug Name(s) | LY2835219 |
Pharmaceutical Developer | Eli Lilly |
D05SBO | TTD Drug ID |
ABEMACICLIB | GuideToPharmacology Ligand Name |